CliffBio
biologic

Esperoct

Antihemophilic Factor (Recombinant), GlycoPEGylated-exei

Loss of exclusivityJuly 2036projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameEsperoct
Active ingredientAntihemophilic Factor (Recombinant), GlycoPEGylated-exei
Strength5000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2024
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Esperoct patent cliff — loss of exclusivity July 2036 | CliffBio